Get started with EndoPredict by downloading the provider product overview.
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
EndoPredict empowers you to confidently determine the necessity and duration of hormone therapy and adjuvant chemotherapy by providing an accurate assessment of recurrence risk across years 0-15, in patients with ER+, HER2–, node-negative (N0), or node-positive (N+) breast cancer.1-3
EndoPredict is a next-generation genomic test that provides three distinct, individualized results to guide confident breast cancer treatment decisions.
EndoPredict provides clarity in the complex decisions around breast cancer treatment by predicting recurrence risk up to 15 years.
EndoPredict helps you answer:
1
What is the chance my patient’s cancer will return within 10 years?
2
How will their cancer potentially respond to chemotherapy?
3
Can they safely stop hormone treatment (endocrine therapy) at five years?
EndoPredict accurately identifies low-risk patients, enabling many to avoid unnecessary chemotherapy and extended endocrine therapy, ensuring that only those who truly need it receive more aggressive treatment.1-4,7,8
More than 70% of node-negative patients are identified as low-risk by EndoPredict
Up to 30% of N+ patients are identified as low risk by EndoPredict
For a complete approach to breast cancer risk management and treatment planning, EndoPredict should be combined with MyRisk and Precise Tumor to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
MyRisk accurately identifies patients at higher genetic risk for breast cancer, enabling more proactive and personalized management strategies. Offering the industry’s lowest rates of BRCA1/2 variants of uncertain significance and a lifetime commitment to variant reclassification, MyRisk allows you to confidently tailor screening plans, assess preventive surgery needs, and identify hereditary cancer syndromes for proactive, personalized management strategies.
Precise Tumor analyzes over 500 genes as well as key biomarkers such as microsatellite instability (MSI), tumor mutational burden (TMB), hormone receptor status (HER2, ER, PR), to identify comprehensive guideline-approved targeted treatment options and clinical trials for advanced solid tumors in breast cancer.4
Provider completes the test request form (in the portal or via paper TRF)
Myriad’s laboratory processing staff contacts your pathology partner to directly obtain the tumor sample.
Results are sent to the ordering provider (in the portal or via mail)
EndoPredict provides a clinically actionable genomic assessment of recurrence risk up to 15 years to determine the necessity and duration of hormone therapy and adjuvant chemotherapy.
Transparent pricing for genetic results with financial assistance and other affordability options.
Treatment-focused reporting includes actionable summaries with clear information to guide surgical decisions.
References:
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.